Margit (Maggie) Janát-Amsbury

Margit (Maggie) Janát-Amsbury has a diverse and extensive work experience in the field of medical research and pharmaceuticals. Their most recent role is the Chief Medical Officer at Halia Therapeutics, Inc. since 2023. Prior to that, they worked at the University of Utah School of Medicine from 2007 to 2018, where they held various positions including Research Associate Professor in the Division of Gynecologic Oncology. Margit (Maggie) also maintained adjunct faculty positions with the Departments of Pharmaceutics and Pharmaceutical Chemistry and Bioengineering at the same university.

In addition to their work at the University of Utah, Janát-Amsbury has held positions at Amgen, where they served as an Executive Medical Director and Product Team Lead in the field of oncology from 2020 to 2023. Margit (Maggie) also worked as a Senior Medical Director at Tolero Pharmaceuticals, Inc. and Sumitomo Dainippon Pharma Oncology from 2018 to 2020.

Janát-Amsbury has a strong interest in nanomedicine and served as the Co-Director of the Center for Nanomedicine at the Utah Nano Institute from 2018 to 2023. Margit (Maggie) also has international experience, having served as a Board Member at the U-I DDS and NT Research Center at Inha University in South Korea from 2011 to 2023.

Furthermore, Janát-Amsbury has established their own consulting firm called ONConcult, LLC, where they worked as a Principal from 2008 to 2018. The company specializes in the translation of novel anticancer therapeutics into clinical application and Janát-Amsbury has extensive experience in clinical trial design, FDA regulations, and monitoring.

Overall, Margit (Maggie) Janát-Amsbury has a wide-ranging work experience spanning academia, pharmaceutical companies, nanomedicine research, international collaborations, and their own consulting firm. Their expertise lies in gynecologic oncology, early development oncology, and the translation of novel therapeutics into clinical application.

Margit (Maggie) Janát-Amsbury's education history starts in 1992 when they attended the University of Cologne, where they received a Doctor of Medicine (MD) degree in Medicine in 1998. During this period, they were also enrolled in the Obstetrics and Gynecology Residency Program and earned a Doctor of Philosophy (PhD) degree in Oncology and Cancer Biology.

In 2002, Margit enrolled at the University of Utah and pursued a dual MD-PhD program focusing on Drug-, Gene Delivery, Pharmaceutical Sciences, and Nanotechnology. Margit (Maggie) completed this program in 2004 and received their MD and PhD degrees.

Continuing their academic journey, Margit attended both Baylor College of Medicine and Maastricht University from 2005 to 2007. At Baylor College of Medicine, they obtained an MD-PhD degree specifically in Gynecologic Oncology, and at Maastricht University, they earned an additional MD-PhD degree in the same field of study.

Margit's final reported educational experience is from the University of Utah School of Medicine, where they pursued further specialization in Gynecologic Oncology. The start year is indicated as 2007, but there is no end year mentioned.

Overall, Margit's education history includes multiple degrees in various fields of study such as Medicine, Gynecologic Oncology, Obstetrics and Gynecology Residency Program, Oncology and Cancer Biology, and Drug-, Gene Delivery, Pharmaceutical Sciences, and Nanotechnology.